INSIGHTS ON CELL & GENE COMMERCIALIZATION ISSUES

• Amgen Bets On Agility In The Age Of AI

  The company is speeding up process optimization with tools like predictive analytics, digital twins, and generative AI copilots.

• Strategic Logistics: Crafting Scalable Solutions For Maximum Reach And Success

  Is your supply chain ready for a blockbuster cell and gene therapy launch? Industry leaders discuss selecting partners, managing risk, and scaling operations for maximum reach and success.

• Maximizing Impact: Strategies For Building Robust Patient Support Programs

  Panelists explore the entire patient journey, from diagnosis to treatment, sharing strategies for creating practical, seamless support systems that ensure access to innovative cell and gene therapies.

• The Power Of Integrated Distribution Strategies

  Discover the power of integrated distribution for cell and gene therapies. Learn from expert speakers how adaptable partnerships can successfully bring these innovative treatments to more patients.

• The Hidden Risk In Cell & Gene Therapy Commercialization

  Of the root causes of new product launch failure, insufficient relative advantage is by far the most important. Let's take a closer look at lessons we can learn from two key (approved) cell therapies.

• A Road Map For Transitioning From A Research-Focused To Commercialization Mindset

  As the timeline for commercialization closes in, it’s necessary to best position the organization for a successful launch. Where to start?

• Accelerating Cell Therapy Development, Manufacturing Workflows

  Realizing the full potential of modern cell therapies requires optimizing every stage of the process. Explore how advanced solutions can accelerate your development and manufacturing pipeline.

• How Combining Best-Of-Breed Technology And Services Can Ensure Commercial Success

  Current "end-to-end" automation often forces sacrifices in cell therapy manufacturing. A strategy integrating specialized technologies for key bottlenecks like activation and expansion aims to improve efficiency.

• Navigating Regulatory Complexity In CGT Development, Commercialization

  To successfully commercialize cell and gene therapies, understanding evolving US regulatory mandates is key. Consider these strategies to avoid delays and ensure compliance.

• Why Better Manufacturing Is the Key to Unlocking Cell Therapy's Full Potential

  Emerging technologies are beginning to address the complex manufacturing challenges that have limited the scalability and accessibility of CAR-T and other cell therapies.